{"product_id":"ept202","title":"Recombinant Human TNF alpha (N-6His)","description":"\u003cstrong\u003eDescription:\u003c\/strong\u003e Recombinant Human Tumor Necrosis Factor Alpha is produced by our E.coli expression system and the target gene encoding Gly57-Leu233 is expressed with a 6His tag at the N-terminus.\u003cbr\u003e\u003cstrong\u003eAccession:\u003c\/strong\u003e P01375\u003cbr\u003e\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 21.8 KDa\u003cbr\u003e\u003cstrong\u003eApparent molecular weight:\u003c\/strong\u003e 18 KDa, reducing conditions\u003cbr\u003e\u003cstrong\u003eOther names:\u003c\/strong\u003e Tumor Necrosis Factor; Cachectin; TNF-Alpha; Tumor Necrosis Factor Ligand Superfamily Member 2; TNF-a; TNF; TNFA; TNFSF2\u003cbr\u003e\u003cstrong\u003eStorage condition:\u003c\/strong\u003e Lyophilized protein should be stored at \u0026lt; -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at \u0026lt; -20°C for 3 months.\u003cbr\u003e\u003cstrong\u003ePurity:\u003c\/strong\u003e Greater than 95% as determined by reducing SDS-PAGE.\u003cbr\u003e\u003cstrong\u003eEndotoxin:\u003c\/strong\u003e Less than 0.1 ng\/µg (1 EU\/µg) as determined by LAL test.\u003cbr\u003e\u003cstrong\u003eRedissolve:\u003c\/strong\u003e Always centrifuge tubes before opening.Do not mix by vortex or pipetting.\nIt is not recommended to reconstitute to a concentration less than 100μg\/ml.\nDissolve the lyophilized protein in distilled water.\nPlease aliquot the reconstituted solution to minimize freeze-thaw cycles. \u003cbr\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e Lyophilized protein should be stored at \u0026lt; -20°C, though stable at room temperature for 3 weeks.\nReconstituted protein solution can be stored at 4-7°C for 2-7 days.\nAliquots of reconstituted samples are stable at \u0026lt; -20°C for 3 months.\u003cbr\u003e\u003cstrong\u003eDelivery condition:\u003c\/strong\u003e The product is shipped at ambient temperature.\nUpon receipt, store it immediately at the temperature listed below.\u003cbr\u003e\u003cstrong\u003eBackground:\u003c\/strong\u003e Tumor Necrosis Factor-α (TNF-α) is secreted by macrophages, monocytes, neutrophils, T-cells, and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-α while cells that express CD8 secrete little or no TNF-α. Synthesis of TNF-α can be induced by many different stimuli including interferons, IL2, and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-α has been limited by the proinflammatory side effects such as fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-α mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-α that binds to murine TNF-R55 but not murine TNF-R7, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-α, which binds to both murine TNF receptors. Based on these results, many TNF-α mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-α High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8, Lys9, Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.","brand":"ELK Biotechnology","offers":[{"title":"50ug","offer_id":50413880181016,"sku":"EPT202","price":819.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/5652\/1400\/files\/ELK_31792bc2-f4a7-4435-835d-c3400718f67c.jpg?v=1751164052","url":"https:\/\/danabiosci.com\/products\/ept202","provider":"Dana Bioscience","version":"1.0","type":"link"}